<SEC-DOCUMENT>0001193125-23-145582.txt : 20230516
<SEC-HEADER>0001193125-23-145582.hdr.sgml : 20230516
<ACCEPTANCE-DATETIME>20230516060957
ACCESSION NUMBER:		0001193125-23-145582
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230516
FILED AS OF DATE:		20230516
DATE AS OF CHANGE:		20230516

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		23925496

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d485488d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated May&nbsp;16, 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 33, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><A HREF="d485488dex991.htm">Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell
 Lung Cancer </A></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: May&nbsp;16, 2023 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d485488dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g485488d2.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>of Eftilagimod Alpha in <FONT STYLE="white-space:nowrap">Non-Small</FONT> Cell Lung Cancer </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; 16</B><B></B><B>&nbsp;May </B><B>2023 &#150;</B> I<U>mmutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the
Company&#148;), a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and autoimmune disease, today announces it has received positive feedback from the US Food and Drug
Administration (FDA), regarding the Company&#146;s late-stage clinical development plans for its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT>
protein and MHC Class&nbsp;II agonist, eftilagimod alpha (&#147;efti&#148;), for the treatment of 1st line <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA is supportive of a registrational trial to evaluate efti in combination with an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy based on the encouraging data from the Phase II <FONT STYLE="white-space:nowrap">TACTI-002,</FONT> Part A (N=114) in 1st line NSCLC patients, no matter
their level of <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression, <U>presented in a late-breaking oral abstract presentation</U> at the 37th Annual Society of Immunotherapy of Cancer (SITC) Meeting in November 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Among the items discussed at the meeting were the toxicological package and general aspects of the trial design, including statistics and potential patient
population with a focus on 1st line NSCLC patients with a Tumor Proportion Score (TPS) <FONT STYLE="white-space:nowrap">PD-L1</FONT> of <U>&gt;</U>1% for which efti plus pembrolizumab has already <U>received Fast Track designation</U>. This trial
will be named <FONT STYLE="white-space:nowrap">TACTI-004</FONT> (<B>T</B>wo <B>ACT</B>ive <B>I</B>mmunotherapies). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Immutep CEO, Marc Voigt, commented:
</B>&#147;In light of our compelling clinical data that efti has generated in combination with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy, this meeting with the FDA is a critical step in our
late-stage development process for 1st line <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer. We are thankful for the positive feedback as we continue moving forward with our unique immuno-oncology approach for the many cancer
patients impacted by this difficult disease.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Immutep CSO, Dr.</B><B></B><B>&nbsp;Fr&eacute;d&eacute;ric Triebel, stated:</B> &#147;We are very
pleased with our constructive dialogue with the FDA establishing a clear path forward for efti in front line <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer. These interactions represent an important milestone within
Immutep&#146;s three main clinical programs targeting cancers that affect large patient populations, positioning efti to make a significant impact for the many patients in need of more effective, tolerable, and durable immunotherapy.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Eftilagimod Alpha (Efti) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is Immutep&#146;s
proprietary soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and MHC Class&nbsp;II agonist that stimulates both innate and adaptive immunity for the treatment of cancer. As a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC) activator, efti binds to MHC (major histocompatibility complex) Class&nbsp;II molecules on APC leading to activation and proliferation of CD8+ cytotoxic T cells,
CD4+ helper T cells, dendritic cells, NK cells, and monocytes. It also upregulates the expression of key biological molecules like <FONT STYLE="white-space:nowrap">IFN-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> and CXCL10 that further
boost the immune system&#146;s ability to fight cancer. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g485488d2.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is under evaluation for a variety of solid tumours including <FONT STYLE="white-space:nowrap">non-small</FONT> cell
lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and HER2&#150;/HR+ metastatic breast cancer. Its favourable safety profile enables various combinations, including with <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-[L]1</FONT></FONT> immunotherapy and/or chemotherapy. Efti has received Fast Track Designation in 1st line HNSCC and in 1st line NSCLC from the United States Food and Drug Administration (FDA). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a clinical stage biotechnology
company leading the development of <FONT STYLE="white-space:nowrap">LAG-3</FONT> related immunotherapy products for the treatment of cancer and autoimmune disease. The Company is dedicated to leveraging its technology and expertise to bring
innovative treatment options to market for patients and to maximise value to shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep&#146;s lead product candidate is eftilagimod alpha
(&#147;efti&#148; or &#147;IMP321&#148;), a soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> fusion protein <FONT STYLE="white-space:nowrap">(LAG-3Ig),</FONT> which is a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC) activator being explored in cancer in multiple clinical trials. The Company is also developing an agonist of <FONT
STYLE="white-space:nowrap">LAG-3</FONT> (IMP761) for autoimmune disease. Additional <FONT STYLE="white-space:nowrap">LAG-3</FONT> product candidates, including antibodies for immune response modulation, are licensed to and being developed by
Immutep&#146;s large pharmaceutical partners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further information can be found on the Company&#146;s website <U>www.immutep.com</U> or by contacting:
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong,
Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268; <U>cstrong@citadelmagnus.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor
Relations and Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the Board of Immutep Limited. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;33, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g485488d2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g485488d2.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /W\H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M.$;8;2WAMHEZXC@C$:#/LJ@5]3"+4(+;E7_ /V"G%TH4XO=12^Y%RK- H *
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MBNVC1I4(J,(I6ZGL8+ 83+:/L,%1C1@_B=KR?ST9U@&/P_"M3LUZZVV%H *
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M=1QFR!')8D _26@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@#]2: "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * /!/C?\-]>^(MCH-MH4VG02:7=WL]Q_:,\\"E+B&)$$1AMI2S!D.<
M@<=ZX,QPL\33IPIZ.#O^7;;8^=XARC$YI3HQHN,?9.^KWV]+;>9M^ /!.K^&
M?AH?"&H263:H+37( ]M+*]IOU&6[>W/F/ CA0LZ[CY9P58#..=*&'E1PSH7Y
MG+K:UKKMUMZG3E6 JX+*_JE5VE&[O;]+]/4\O^#WP7\5^ /%KZ[K5QH\MFVD
MWEB$L+JYFG$T\UHZ$I+9Q+Y86%R3NSP./3CR_ U<-5=2II=;6_7_ (!XW#_#
MN,RW&O$5I1<6K66G;K=_D>P_%SPEJ?C?P5?>'='DM(KVYNM/GC>]DDBMPEI=
MQ7$@9XH96#;$(&%ZUU8RE*M1]E#?OV/<SC U,?EU;#TGRRJ6UM>WRNK_ ('+
M_ _X=:[\.M,UVTUV;3II=0OK6X@_LZ:>=42"W>)A(9K:'#;F' !&.^>*67X>
MIAZ;IS5F<?#N4XC*\/5I5G&3J.]UI;2VVM_O*/QR^&/B'XCGPU_8,VF0?V.=
M5-U_:-Q/;[OMIT]H?)\FUFW8-I(&SMQE<9R<9YC@ZF)]C[/3V3OMOTZ;;&7$
M>2XO-/8>P<8^Q[N]_P K?B=KX'\)ZEX<^'-EX3OI+5M2MM-U.UD>WDD>U\R]
MN;V:+;(\2/M N4!)C'W3@&MJ%)T,&J-^9J^NWX:GIY;@JF$RFC@ZCLZ*MS6W
M^5]/O9Y!\'?@OXK\ >+GUW6KG1I;-M(O+!5L+JYFF\ZXGLW0[9;*)=@6!\G=
MG.!CG(X\NP%7#5G5J.UTURV_7_@'A9!P]B\JQU2O6E&4'!JRT_5GJOQC\%ZM
MX\\(?V#HLEG%>+J=G>[KZ66*#RK=+A&7=#!*V\F5<?)C@\UV8VC*M25.+Y=4
MT_3H>QGF JYCE[P])\LI233M?;RNC-^"G@+6OAYX>U/2=<EL)KB[UF34(6T^
M::>(0/8:?; ,9K>(A_-MI. ",8.><"<!A:F'I3IST<G>YCP]E6)RS#5*5;E?
M,[W3M;Y:_H<S\;_A3XD^(NH:#=Z%/I4,6EVEY!.-0N+B!V>XG@D3RUAM)05"
MQ-G)'TK',<%4Q,Z;AIR*STO_ %8Y.(LDQ>:2I2HN,525M[_AH>O> =#O/#/@
M[0/#^H- U[I6FP6=PUL[O TD2E6:)I(XV*9S@E%/'2NW#0=.C3I_\^X\M^_^
M7XGN9=AIX+ T*,]94E;M_P ,?$WQ7_8\UB]U^^\1?#+4-.AM[^ZEOI?#NH3S
M:>VGW<SM++_9%]%%(C6WFL62*4PF($JKLH"KN=QYS-^S/^TAKD*Z;K6JK)IZ
MLF(=:\;7%]8#RR/+*VJ2W7W, J?*XZB@#[#_ &<_@[KGP?T+7M.U[4]*U&ZU
MO4;2^4:2;MK>V2WM7MS&9;NW@>5F+@Y$2@8(SW)L&QY_^T'^S%>?$77#XR\&
MW]A::_/:P6^KZ;JADM[/53:(L%M=P7D$4A@OEM8HH&1T\MU@B;<C*QD/T#]#
MP.U_9I_:0O((]"O-=^P:(BB'R+SQM>7&DI N5")IUD]P3&!C""W0  < @8 /
MT:'A>'6?!,/A3Q<EMK*7&@VFD:[\KB"_GCLXH;JYB)*R0E[A#-&X8.A",&#*
M#0!^?OB[]C/QQH>JMJ'PX\06NHV*2^;817E]+HWB"QY_=QB[CC^S7#)D#SUF
MM2P',2C()MY!MY&6G[-'[1WB,"Q\1>(O(T\%4==?\::AJEJ$''RVEHUZ2 ,X
M7:H['K0!]O\ Q)LKO3?@'XPTZ_G2[OK#X;:A9WEU$K)'<W5IH1@N+B-'^9$D
MEC=P&Y 8#M0!^5WPC^%OBGXGZCJ\'@_5;/2]8\/6$&J1-=W-Y8F19;F.UVVU
MY91.\$RER<D $=66@#VQ?V5/CSXIO[>/Q7KEDMM =G]H:YXGO-=-O$V QL[=
M//DR1DA"8 >[#.:/T#]#[Z^$OPHT+X2>&(] T=WN[F:;[9K&K3QK'<ZK?E%C
M\UD5B(+:.-?+A@#,(UR<M(\CN;?(-OD>J4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MP(R<9(!\2_L,_P#(Y>-?^Q8L_P#TZP4 ?IC0 4 % !0 4 % !0 4 % !0 4
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MWTGA"&UM;.*S\,ZM:SBW/F1(FDVUA<0QV$*0 AX5OH](F%O)MA)L(6(W0)@
MG^(OA^]\4> _%WAC3'MHK_7O#VJZ3927LDL5I'<7MG);PM<20PS2)"&8%BD3
MG&2%- 'SC^S=\ _&7P@\0^(=4\2W_AR\MM6T>WTZV71+S4;F9)HKV.X9ITO=
M)M%2/8A&5=SGJ*-@V/L.@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M_P#/W\ _UDRG_G_^ ?\ "_OA3_T-"_\ @JUS_P"5E']HX/\ Y^_@'^LF4_\
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M_P  _P"%_?"G_H:%_P#!5KG_ ,K*/[1P?_/W\ _UDRG_ )__ (!_PO[X4_\
M0T+_ ."K7/\ Y64?VC@_^?OX!_K)E/\ S_\ P#_A?WPI_P"AH7_P5:Y_\K*/
M[1P?_/W\ _UDRG_G_P#@'_"_OA3_ -#0O_@JUS_Y64?VC@_^?OX!_K)E/_/_
M / /^%_?"G_H:%_\%6N?_*RC^T<'_P _?P#_ %DRG_G_ /@'_"_OA3_T-"_^
M"K7/_E91_:.#_P"?OX!_K)E/_/\ _ /^%_?"G_H:%_\ !5KG_P K*/[1P?\
MS]_ /]9,I_Y__@'_  O[X4_]#0O_ (*M<_\ E91_:.#_ .?OX!_K)E/_ #__
M  #_ (7]\*?^AH7_ ,%6N?\ RLH_M'!_\_?P#_63*?\ G_\ @'_"_OA3_P!#
M0O\ X*M<_P#E91_:.#_Y^_@'^LF4_P#/_P# /^%_?"G_ *&A?_!5KG_RLH_M
M'!_\_?P#_63*?^?_ . ?\+^^%/\ T-"_^"K7/_E91_:.#_Y^_@'^LF4_\_\
M\ _X7]\*?^AH7_P5:Y_\K*/[1P?_ #]_ /\ 63*?^?\ ^ ?\+^^%/_0T+_X*
MM<_^5E']HX/_ )^_@'^LF4_\_P#\ _X7]\*?^AH7_P %6N?_ "LH_M'!_P#/
MW\ _UDRG_G_^ ?\ "_OA3_T-"_\ @JUS_P"5E']HX/\ Y^_@'^LF4_\ /_\
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MP#_63*?^?_X!_P +^^%/_0T+_P""K7/_ )64?VC@_P#G[^ ?ZR93_P __P
M_P"%_?"G_H:%_P#!5KG_ ,K*/[1P?_/W\ _UDRG_ )__ (!_PO[X4_\ 0T+_
M ."K7/\ Y64?VC@_^?OX!_K)E/\ S_\ P#_A?WPI_P"AH7_P5:Y_\K*/[1P?
M_/W\ _UDRG_G_P#@'_"_OA3_ -#0O_@JUS_Y64?VC@_^?OX!_K)E/_/_ / /
M^%_?"G_H:%_\%6N?_*RC^T<'_P _?P#_ %DRG_G_ /@'_"_OA3_T-"_^"K7/
M_E91_:.#_P"?OX!_K)E/_/\ _ /^%_?"G_H:%_\ !5KG_P K*/[1P?\ S]_
M/]9,I_Y__@'_  O[X4_]#0O_ (*M<_\ E91_:.#_ .?OX!_K)E/_ #__  #_
M (7]\*?^AH7_ ,%6N?\ RLH_M'!_\_?P#_63*?\ G_\ @'_"_OA3_P!#0O\
MX*M<_P#E91_:.#_Y^_@'^LF4_P#/_P# /^%_?"G_ *&A?_!5KG_RLH_M'!_\
M_?P#_63*?^?_ . ?\+^^%/\ T-"_^"K7/_E91_:.#_Y^_@'^LF4_\_\ \ _X
M7]\*?^AH7_P5:Y_\K*/[1P?_ #]_ /\ 63*?^?\ ^ ?\+^^%/_0T+_X*M<_^
M5E']HX/_ )^_@'^LF4_\_P#\ _X7]\*?^AH7_P %6N?_ "LH_M'!_P#/W\ _
MUDRG_G_^ ?\ "_OA3_T-"_\ @JUS_P"5E']HX/\ Y^_@'^LF4_\ /_\  /\
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MQZ!_WQJ/_P C4?V)7_GA][_R#_4G$_\ 070_\G_R#_AE;Q9_T,>@?]\:C_\
M(U']B5_YX?>_\@_U)Q/_ $%T/_)_\@_X96\6?]#'H'_?&H__ "-1_8E?^>'W
MO_(/]2<3_P!!=#_R?_(/^&5O%G_0QZ!_WQJ/_P C4?V)7_GA][_R#_4G$_\
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MQZ!_WQJ/_P C4?V)7_GA][_R#_4G$_\ 070_\G_R#_AE;Q9_T,>@?]\:C_\
M(U']B5_YX?>_\@_U)Q/_ $%T/_)_\@_X96\6?]#'H'_?&H__ "-1_8E?^>'W
MO_(/]2<3_P!!=#_R?_(/^&5O%G_0QZ!_WQJ/_P C4?V)7_GA][_R#_4G$_\
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MH\W-HT]+JWKY'W%7TA^B!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
54 % !0 4 % !0 4 *O44(<=T?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
